Evidence map›Paper›PMID 37083601›Full record

ArticleBioscience reports2023

PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.

Feng Xiao, Xinfang Jie, Xiang Zhou, Yun Guo, Gu Feng Sun, Li Lin, Guo Wen Hu, Kai Huang, Hua Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Feng Xiao *Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xinfang Jie *Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Xiang Zhou *Department of Neurosurgery, Fuzhou First People's Hospital, Fuzhou, Jiangxi, China.
Yun GuoDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Gu Feng SunDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Li LinDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Guo Wen HuDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Kai HuangDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Hua GuoDepartment of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.ORCID 0000-0002-1372-170X
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe specific functions of PPP1R81 has been elucidated in multiple cancers; however, its role in lower-grade glioma (LGG) remains unknown. In this research, we inspected the specific role of PPP1R81 in LGG.

methodsWe totally evaluated the expression pattern and prognostic role of PPP1R81 in multitudinous tumors. Subsequently, we systematically examined the connection between PPP1R81 expression and prognosis, clinical characteristics, biological functions, genetic variations, and immunological characteristics in LGG according to the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Altas (CGGA) databases. In vitro experiments were executed to inspect the expression level and specific roles of PPP1R81 in LGG.

resultsPPP1R81 was elevated in multiple tumors and was tightly linked to a poor prognosis. LGG with higher expression of PPP1R81 showed poorer prognosis compared with lower expression of PPP1R81. The results of univariate and multivariate Cox regression analyses confirmed that the expression of PPP1R81 was an independent prognostic biomarker of LGG. Immune cell infiltration, immune checkpoint genes (ICPGs), copy number alterations (CNA), and tumor mutation burden (TMB) were also closely associated with PPP1R81 expression in LGG. In vitro experiments demonstrated that PPP1R81 was up-regulated and closely interrelated with cell proliferation and cell cycle in LGG.

conclusionPPP1R81 was an independent prognostic signature and underlying therapeutic target for patients with LGG.

Indexed as

Brain NeoplasmsGliomaCarrier ProteinsCell CycleCell Cycle ProteinsCell DivisionCell ProliferationHumansNuclear ProteinsCarrier ProteinsCDCA2 protein, humanCell Cycle ProteinsNuclear Proteinscell proliferationimmune infiltrationlower-grade gliomaPPP1R81prognostic signature

Identifiers

PMID37083601
PMCPMC10170297
OpenAlexW4366603676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.